NKGN (NKGen Biotech) Retained Earnings: $-191.07 Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is NKGen Biotech Retained Earnings?

NKGen Biotech NKGN Retained Earnings is $-191.07 Mil as of Mar. 2025.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. NKGen Biotech's retained earnings for the quarter that ended in Mar. 2025 was $-191.07 Mil.

NKGen Biotech's quarterly retained earnings declined from Sep. 2024 ($-177.00 Mil) to Dec. 2024 ($-206.42 Mil) but then increased from Dec. 2024 ($-206.42 Mil) to Mar. 2025 ($-191.07 Mil).

NKGen Biotech's annual retained earnings declined from Dec. 2022 ($-79.18 Mil) to Dec. 2023 ($-162.13 Mil) and declined from Dec. 2023 ($-162.13 Mil) to Dec. 2024 ($-206.42 Mil).

NKGen Biotech  (OTCPK:NKGN) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

NKGen Biotech Retained Earnings Historical Data

* Premium members only.

The historical data trend for NKGen Biotech's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NKGen Biotech Retained Earnings Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Retained Earnings
-52.42 -79.18 -162.13 -206.42

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -167.51 -183.60 -177.00 -206.42 -191.07

NKGen Biotech Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-191.07 Mil mean?
NKGen Biotech (NKGN) has a Retained Earnings of $-191.07 Mil as of Mar. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on NKGen Biotech and its competitors.
Is NKGen Biotech's Retained Earnings too high?
NKGen Biotech's current Retained Earnings is $-191.07 Mil.
How does NKGen Biotech's Retained Earnings compare to CALC and CLGN?
NKGen Biotech's Retained Earnings of $-191.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on NKGen Biotech and its competitors. NKGen Biotech's current Retained Earnings is $-191.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NKGen Biotech stock overvalued right now?
NKGen Biotech (NKGN) has a current Retained Earnings of $-191.07 Mil. The current Retained Earnings is $-191.07 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For NKGen Biotech (NKGN), the current Retained Earnings is $-191.07 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NKGen Biotech Business Description

Address 3001 Daimler Street, Santa Ana, CA, USA, 92705
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.